Issue 34
For decades, successful pharmaceutical manufacturing has been judged on scale. Nowadays, higher precedence is being given to speed, coping with complexity, and customization…
Issue 33
CDMO partnerships are great when they are successful, but what happens when they falter? The complexity of modern outsourcing partnerships means that failure is often costly, with consequences…
Issue 32
Biopharma companies are increasingly dependent on CDMOs to streamline production, enhance efficiency, and accelerate drug development. As therapies become more complex and regulatory demands grow, the ability to…
Issue 31
Pharmaceutical manufacturing is the backbone of global healthcare, yet its environmental footprint is a growing concern. The sector is responsible for significant greenhouse gas emissions, excessive water consumption,…
Issue 30
India’s pharmaceutical industry has long been synonymous with cost-effective pharmaceutical manufacturing - particularly when it comes to generic drugs. In recent years, India has been making a significant…
Issue 29
The global biologics market is expected to reach USD 720 bn by 2030, fueled by increasing demand for biologics, biosimilars, and advanced therapies. It is undoubtedly an area…
Issue 28
As the demand for advanced therapies continues to grow, CDMOs are fast becoming the solution for biopharma companies that need specialized expertise and capabilities that are scalable for…
Issue 27
The CDMO industry saw significant growth in 2024, as biotech and pharmaceutical companies continued the trend toward outsourcing R&D activities. This surge was evident in the global CDMO…
Issue 26
Overall, 2024 was a good year to be working in the CDMO industry, but will the outlook stay positive for 2025? Forecasts predict a steady rise in continuing…
Issue 25
The term CDMO has become ubiquitous in the pharmaceutical industry over the past decade, but is it merely a buzzword or does it represent a genuine paradigm shift?
Issue 24
If you were to launch a biopharma startup today, where would you find the skills, talent, and space to bring your vision to life? Biopharma incubators are usually…
Issue 23
Last month, hedge fund Starboard Value acquired a $1 bn stake in Pfizer, at the same time, sharply criticizing the company's management for recent underperformance and strategic missteps…
